A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

• Status: Recruiting
• Trial end date: 2027-12-06
• Target enrollment: 0
• Participant gender: All

Summary

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participants must have completed a previous study of baricitinib for the treatment of JIA.

Exclusion Criteria:

• Participants must not have had a permanent discontinuation of baricitinib in the prior study.

• Participants must have not developed an allergy to baricitinib.